Market Overview

Deutsche Bank Reiterates Buy on Vertex Pharmaceuticals Following Press Release

Share:
Related VRTX
Biogen And Gilead Sciences Catch The Eye Of Short Sellers
4 Biotechs Piper Jaffray Is Buying On The Pullback
Premarket Biotech Digest: CLL Treatment, Gilead CEO Sells, Acelity IPO (Seeking Alpha)

Following the press release issued earlier Tuesday morning by Vertex Pharmaceuticals (NASDAQ: VRTX), Deutsche Bank analyst, Robyn Karnauskas reiterated the firm's Buy rating and $103.00 price target for Vertex shares.

Karnauskas wrote, "Bottom line: We believe that this is the first step in Vertex platform treating entire cystic fibrosis population." Karnauskas based this on the belief that doctors will use the regimen for the high unmet need among the cystic fibrosis community for a viable treatment.

For a more detailed look into the press release see Why Is Vertex Pharmaceuticals Up More Than 50 Percent?

Latest Ratings for VRTX

DateFirmActionFromTo
Jul 2015JMP SecuritiesMaintainsMarket Outperform
Jul 2015Bank of AmericaMaintainsNeutral
Jul 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (VRTX)

Get Benzinga's Newsletters